Coronary Artery Disease

Coronary artery disease (CAD) is characterized by the development of atherosclerotic plaques within the coronary arterial system, leading to progressive narrowing of the vessel lumen and potentially resulting in inadequate myocardial blood supply relative to metabolic demand. CAD is the leading cause of morbidity and mortality in developed nations, with an estimated prevalence of 6-7% in American adults and responsible for approximately 1 in 5 deaths in the United States. The disease spectrum ranges from asymptomatic atherosclerosis detected incidentally to acute myocardial infarction (AMI), and affects men earlier in life (typically presenting in the 5th-6th decade) whereas women have delayed presentation by approximately 7-10 years due to estrogen-mediated cardioprotection until menopause. Understanding CAD is essential for clinical practice because early identification through risk stratification, aggressive secondary prevention, and appropriate revascularization can substantially reduce ischemic events and improve survival; furthermore, CAD pathophysiology integrates multiple fundamental cardiovascular concepts tested extensively on medical board examinations.

CAD results from the complex interplay between endothelial injury, lipid deposition, inflammatory activation, and smooth muscle proliferation, culminating in atherosclerotic plaque formation that progressively restricts coronary blood flow.

The initiating event in atherosclerosis involves functional and structural damage to the coronary endothelium, typically triggered by chronic exposure to cardiovascular risk factors such as hypertension, hyperlipidemia, smoking, and hyperglycemia. These factors increase endothelial permeability to lipoproteins, particularly low-density lipoproteins (LDL), which accumulate in the subendothelial space. Native LDL undergoes oxidative modification through the action of lipoxygenases and other oxidative enzymes, generating oxidized LDL (oxLDL)—a highly immunogenic particle that triggers innate immune recognition via scavenger receptors (particularly SR-A and CD36) on macrophages and endothelial cells. The accumulation of cholesterol-laden macrophages in the subendothelial layer forms the earliest morphological lesion, the fatty streak, which is visible as yellow discoloration on the intimal surface. Paradoxically, oxLDL-laden macrophages (foam cells) may regress or progress depending on local inflammatory milieu and endothelial repair capacity, explaining why not all fatty streaks advance to clinically significant disease.

OxLDL activates endothelial cells to express adhesion molecules including E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1), which facilitate transmigration of circulating monocytes and T lymphocytes into the subendothelial space. Resident and infiltrating macrophages secrete pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines (MCP-1/CCL2, RANTES/CCL5) that perpetuate leukocyte recruitment and activate smooth muscle cells. The oxidized lipids and inflammatory mediators stimulate smooth muscle cell (SMC) migration from the media to the intima and promote their proliferation and transition to a synthetic phenotype, increasing production of extracellular matrix proteins (collagen types I and III, elastin, proteoglycans). This SMC-derived matrix provides structural integrity to the developing atheroma and creates a fibrous cap overlying a lipid-rich necrotic core. The mature atherosclerotic plaque thus comprises an organized architecture: luminal fibrous cap, underlying lipid core with cellular debris, surrounding media of variable thickness, and adventitial inflammation.

Early atherosclerotic lesions are characterized by positive remodeling, wherein the vessel expands outward (Glagov remodeling) to accommodate plaque growth while maintaining luminal diameter—explaining why angiographically "normal" coronary arteries may harbor significant plaque burden detected by intravascular ultrasound. Over time, the degree of remodeling becomes insufficient relative to plaque progression, and the lumen progressively narrows. A >70% diameter stenosis typically produces hemodynamically significant obstruction that limits maximal blood flow and manifests as supply-demand ischemia, whereas >90% stenosis reduces baseline coronary flow reserve substantially. The severity of luminal narrowing correlates imperfectly with ischemic symptoms because myocardial oxygen supply is a product of coronary blood flow and arterial oxygen content, and the distal coronary circulation can develop collateral vessels through arteriogenesis in response to chronic hypoperfusion, partially compensating for stenosis.

Atherosclerotic plaques exist on a spectrum from stable to unstable (vulnerable), with vulnerable plaques characterized by large lipid cores, thin fibrous caps (<65 μm), abundant macrophage infiltration, increased neovascularization, and elevated protease activity. Macrophage-derived matrix metalloproteinases (MMPs)—particularly MMP-2, MMP-9, and membrane-type MMP—degrade collagen and proteoglycans within the fibrous cap, weakening its structural integrity. Plaque destabilization may result from mechanical stress at the shoulder region (junction between plaque and normal vessel), apoptosis of SMCs and macrophages, infection (possibly by Chlamydia pneumoniae or other pathogens), and lipid core accumulation. Plaque rupture occurs when mechanical stress exceeds the tensile strength of the thinned fibrous cap, exposing the highly thrombogenic lipid core and tissue factor-rich macrophages to circulating blood. This exposure triggers simultaneous activation of the extrinsic coagulation pathway (via tissue factor) and platelet aggregation (via collagen and von Willebrand factor), resulting in intracoronary thrombosis. The extent of thrombus determines the clinical consequence: a nonocclusive thrombus may cause unstable angina, whereas an occlusive thrombus precipitates acute transmural myocardial infarction (typically associated with ST-segment elevation on ECG in the distribution of the affected artery).

Coronary blood flow is controlled by metabolic autoregulation (adenosine and other metabolites cause vasodilation to maintain constant flow across a range of perfusion pressures), endothelium-dependent vasodilation (nitric oxide production by endothelial cells), and sympathetic/parasympathetic innervation. A hemodynamically significant coronary stenosis limits the ability of the distal coronary bed to vasodilate (reduce coronary vascular resistance) in response to increased metabolic demand, so any increase in myocardial oxygen consumption (heart rate, contractility, blood pressure) cannot be matched by proportional increases in blood flow. The resulting mismatch between oxygen supply and demand generates myocardial ischemia—a state of inadequate oxygen availability relative to metabolic need. Ischemia impairs oxidative metabolism, causing ATP depletion, accumulation of lactate and hydrogen ions (intracellular acidosis), disruption of calcium homeostasis, and increased diastolic stiffness. Angina pectoris results from ischemia-induced alterations in myocardial electrical activity and mechanical function, triggering visceral afferent nerve signals transmitted via the sympathetic nervous system (particularly T1-T4 spinal segments) that are perceived as substernal discomfort, often radiating to the neck, jaw, shoulders, or arms.

The vast majority of CAD results from atherosclerotic plaque formation driven by traditional cardiovascular risk factors, which act synergistically to accelerate endothelial dysfunction and atherogenesis. These include hypertension (damages endothelium through increased shear stress and promotes SMC proliferation), hyperlipidemia (elevated LDL-C and low HDL-C increase foam cell formation and plaque burden), cigarette smoking (oxidative stress, endothelial dysfunction, increased thrombotic tendency), diabetes mellitus (hyperglycemia impairs endothelial function, increases oxidation of LDL, promotes inflammation), obesity (insulin resistance, systemic inflammation, dyslipidemia), physical inactivity (metabolic dysfunction, impaired endothelial function), male sex and advancing age (endogenous estrogen loss, telomere shortening), and chronic kidney disease (uremia, mineral metabolism disorders, hypertension, inflammation). Family history of premature CAD (before age 55 in men or 65 in women) indicates increased genetic predisposition through both inherited risk factors and shared environmental exposures. The Framingham Risk Score and ACC/AHA Pooled Cohort Equations quantify 10-year risk based on age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive treatment, smoking status, and diabetes, enabling risk-stratification and intensification of preventive therapy.

Abnormal plasma lipid profiles substantially accelerate atherosclerosis; elevated LDL cholesterol (particularly small dense LDL particles), elevated triglycerides (associated with increased VLDL and decreased HDL), and decreased HDL cholesterol are all independent risk factors. Familial hypercholesterolemia (FH), caused by mutations in genes encoding the LDL receptor, apolipoprotein B, or PCSK9, results in markedly elevated LDL-C (heterozygous: >300 mg/dL; homozygous: >600 mg/dL) and premature CAD often presenting before age 40. Familial combined hyperlipidemia and familial hypertriglyceridemia confer increased CAD risk through elevations in apoB-containing lipoproteins and impaired triglyceride clearance, respectively. Lipoprotein(a) [Lp(a)], a particle consisting of LDL-like apoB100 linked to apolipoprotein(a), is an independent atherogenic and thrombogenic risk factor; genetically elevated Lp(a) levels (>50 mg/dL) increase CAD risk substantially and require more aggressive lipid-lowering therapy.

Several systemic inflammatory conditions markedly increase CAD risk through endothelial activation and accelerated atherogenesis: systemic lupus erythematosus (SLE) and antiphospholipid syndrome increase CAD risk through both inflammation and thrombosis; rheumatoid arthritis and psoriasis are independent CAD risk factors through inflammatory cytokine overproduction; inflammatory bowel disease (Crohn's disease and ulcerative colitis) associates with premature CAD; and human immunodeficiency virus (HIV) infection (both from direct viral effects and antiretroviral medications) accelerates atherosclerosis. Chronic kidney disease elevates CAD risk through mineral metabolism derangements (phosphate retention, abnormal vitamin D metabolism), inflammation, hypertension, and dyslipidemia. Obstructive sleep apnea increases CAD risk through repetitive hypoxemia-induced oxidative stress, sympathetic activation, and systemic inflammation.

Elevated fibrinogen, factor VII, and other coagulation factors independently increase CAD risk. Lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory enzyme associated with LDL particles, predicts coronary events and may serve as a biomarker for atherosclerotic burden. Elevated plasma homocysteine (hyperhomocysteinemia) from genetic variants in methylenetetrahydrofolate reductase (MTHFR) or nutritional deficiencies (B6, B12, folate) promotes endothelial dysfunction and thrombosis, though whether homocysteine lowering reduces CAD risk remains controversial.

Diabetes mellitus substantially accelerates atherosclerosis through multiple mechanisms: hyperglycemia-induced generation of advanced glycation end-products (AGEs) that promote cross-linking and stiffening of collagen, increased oxidative stress and mitochondrial dysfunction, impaired endothelial function, prothrombotic state, and associated dyslipidemia. Prediabetes (impaired fasting glucose or impaired glucose tolerance) also increases CAD risk. Insulin resistance and metabolic syndrome (central obesity, hypertension, dyslipidemia, hyperglycemia) confer additive CAD risk beyond their individual components. Elevated lipoprotein(a) synergizes with LDL-C elevation to further increase atherogenic particle concentration.

Menopause in women associates with loss of estrogen-mediated cardioprotection and acceleration of atherosclerosis; estrogen replacement therapy does not reduce CAD events and may increase thrombotic complications. Oral contraceptive use, particularly in women with additional risk factors, increases thrombotic risk. Chronic stress, depression, and social isolation increase CAD risk through sympathetic activation, endothelial dysfunction, and behavioral changes. Air pollution exposure (particulate matter, ozone) exacerbates atherosclerosis through oxidative stress and inflammation. Excessive alcohol consumption increases hypertension and arrhythmia risk, counteracting any potential benefits of moderate consumption. Migraine with aura associates with increased stroke and myocardial infarction risk, particularly in women on hormonal contraception.

While atherosclerosis accounts for >90% of significant CAD, other pathologic processes can reduce coronary blood flow: coronary artery vasospasm (Prinzmetal angina or vasospastic angina) typically occurs at the site of atherosclerotic lesions but can occur in angiographically normal arteries; coronary artery dissection, either spontaneous (particularly in peripartum women or those with connective tissue disorders) or iatrogenic (during coronary intervention), acutely obstructs flow; coronary artery anomalies (abnormal origin from opposite sinus, intramural course) can restrict flow during exercise; coronary microvascular dysfunction impairs the vasodilatory capacity of small resistance vessels in the absence of obstructive epicardial disease; takotsubo cardiomyopathy (stress-induced) causes transient dysfunction mimicking myocardial infarction; aortic dissection extending into a coronary ostium occludes flow; and emboli to coronary arteries can result from atrial fibrillation, endocarditis, or paradoxical embolism through a patent foramen ovale.

Stable angina is the most common symptomatic manifestation of CAD, characterized by reproducible chest discomfort precipitated by conditions that increase myocardial oxygen demand (exertion, emotional stress, cold exposure, heavy meals) and relieved by rest or nitroglycerin within 5-15 minutes. The discomfort is typically substernal in location and may radiate to the left arm, jaw, neck, shoulder, or back; patients often describe it as pressure, tightness, heaviness, or squeezing rather than sharp pain. Associated symptoms include dyspnea (from increased left ventricular end-diastolic pressure reducing lung compliance), diaphoresis, nausea, and fatigue. The Canadian Cardiovascular Society (CCS) grading system classifies stable angina: Class I (angina with strenuous exertion), Class II (mild limitation with exertion >2 blocks or >10 minutes), Class III (marked limitation with exertion <2 blocks or <10 minutes), and Class IV (angina at rest or with minimal activity). The predictability of symptoms and full resolution with rest distinguishes stable angina from unstable angina or acute myocardial infarction. Angina severity correlates imperfectly with stenosis severity because collateral development, plaque composition, and endothelial function modulate symptom expression.

Unstable angina represents a critical transition state and is classified as part of the acute coronary syndrome (ACS) spectrum. It is defined as: (1) new-onset angina (within 2 weeks) that is severe or frequent; (2) acceleration of prior stable angina (occurring with less